Member Info for marik

The 608 coronavirus deaths could have been saved to some extent had they been given SNG001. Regulatory bodies need to reassess or at least expedite the approval of SNG001 post-P3 commencing.

Retail investors are getting very itchy feet. SNG is not a one trick pony or a gimmick. One would expect a huge surge in the share price as news is released on future progress. The vaccine is great news, but the CEOs of Pfizer and others recognise that they are not the magic bullet and that therapeutics alongside vaccines are essential for the fight. This is something they've been aware of months back.

"/youtu.be/-y3Ose3IeXQ?t=3710"

"businessinsider.com/moderna-chief-medical-officer-vaccines-interview-2020-11?r=US&IR=T"

You've lost your mind and think a phase 3 company is worth £170m?

https://www.businessinsider.com/moderna-chief-medical-officer-vaccines-interview-2020-11?r=US&IR=T

A Phase III company with a market cap less than £170m. It should be more than 5 times the market cap at this stage sitting around £4 per share.

Once phase III commences, Synairgen can stop the trial early on very positive news. And that is more likely to happen considering the last set of data. Could be seeing north of £9 a share let alone 85p a share.

Moderna Chief Medical Officer Tal Zaks told Axios that the public should not "over-interpret" the vaccine trial results to assume life could go back to normal after adults are vaccinated.

Zaks warned that the trial results show that the vaccine can prevent someone from getting sick or "severely sick," from COVID-19, however, the results don't show that the vaccine prevents transmission of the virus.